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ABSTRACT
The Adenovirus E1A gene sensitizes cells to genetic insults and apoptosis, most
notably in response to cytotoxic factors from innate immune cells. The mechanisms by
which E1A sensitizes cells to apoptotic stressors have not been fully elucidated, however
E1A actively represses NF-κB anti-apoptotic defenses, thereby sensitizing cells to
alternative apoptotic cascades. Recent studies alternatively indicate that E1A also
actively induces Caspase-2 activation and mitochondrial injury in the presence of certain
cytotoxic injuries.
Caspase-2 is cleaved and activated in a large complex consisting of p53-inducible
protein with a death domain (PIDD), an adaptor protein RAIDD, and pro-caspase 2.
PIDD auto-proteolyzes into several fragments and the C-terminal PIDD-CC fragment is
required for activation of the PIDDosome in response to cytotoxic stress. We
hypothesized that E1A-induced sensitivity and induction of Caspase-2 activity is
dependent on PIDD, and in particular PIDD autoproteolysis to the PIDD-CC fragment.
A PIDD knockdown was generated in mouse fibroblast cells that also expressed E1A to
determine the contribution of PIDD protein to apoptotic sensitivity. A PIDD processingmutant, incapable of terminal processing to the PIDD-CC fragment, was also generated to
establish whether PIDD auto-cleavage is required for E1A-induced sensitivity. We
observed that knockdown of PIDD and inhibition of PIDD processing significantly
decreased sensitivity of E1A-expressing cells, indicating that PIDD indeed plays a role in
v	
  

	
  
the effects of E1A on caspase-2 activation and sensitization to cytotoxic stressors. These
results may ultimately contribute to improvements on the application of Adenovirus E1A
in anti-cancer therapeutics.
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CHAPTER I
INTRODUCTION
Adenoviruses are a family of viruses that were discovered in the mid-1950s from
independent attempts to isolate the causative agent of the “common cold” and identify the
cause of a flu-like epidemic that had infected large groups of army recruits during
WWII1-3. Since that time, the antigenic variety and ubiquity of adenoviruses has been
revealed in studies identifying a variety of mammalian hosts and high percentages of
people possessing antibodies to one or more adenovirus serotypes. For instance, one
study found that nearly 100% of adults in Washington, DC had been exposed to
adenoviruses by age 34 3,4. Most serotypes infect respiratory tissues and cause mild cold
symptoms, but many also affect a variety of organs: besides respiratory disease, common
maladies associated with adenoviruses are gastroenteritis and conjunctivitis 5,6.
Symptomatic adenoviral infection may be as low as 15% or as high as 45%, but these
estimates depend on the adenovirus serotype and symptoms represented 7,8. While
adenoviruses have been studied for over half a century, their pathological mechanisms
have not been fully defined.
For decades, adenoviruses have had applications within research, as the structure
and genome of the virus can be easily manipulated and used as vectors for delivering
genetic material to foreign targets. The adenoviral genome has been well characterized
and utilizes much of the cellular machinery involved in DNA replication, transcription,
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and translation; thus, research on adenoviruses has provided important insights into the
molecular biology of the cell (reviewed in 9). Adenoviruses are uniquely suited as
genetic vectors for several reasons: They produce high titers and infect a wide variety of
cells; the genome can be stably expanded to encode large segments of foreign DNA 10;
and integration of the genome into the host chromosome is rare unless it is hybridized
with retroviruses, allowing investigators plenty of control for producing either transient
or stable gene expression in hosts 11-13. Importantly, certain adenoviral factors, such as
the Early Region 1 A (E1A) gene, have properties that have been applied to successful
cancer-fighting therapies 14,15. A comprehensive understanding of the adenoviral genetic
arsenal can vastly improve both scientific and therapeutic applications of the virus.
Adenoviral influence on tumor development and apoptosis
Many adenovirus serotypes are tumorigenic within the right immunological context, such
as immunocompromised species or newborn rodents with undeveloped immune
systems16. Early investigations determined that immune competent species, including
rodents beyond a few weeks of age, easily defeated Adenovirus-transformed tumors,
while models lacking innate and/or adaptive immune function exhibited high
tumorigenicity (Figure 1a) 17. A series of studies revealed that the E1A gene specifically
reduced tumorigenicity of transformed cell lines and generally increased sensitivity to
immune cells and their various cytotoxic factors 18 (Figure 1b). Several mechanistically
distinct classes of insults from innate and adaptive immune cells were able to sensitize
E1A-expressing cells to cytolytic injuries, including Fas ligand, Tumor Necrosis Factor
alpha (TNFalpha), TNF-related Apoptosis Inducing Ligand (TRAIL), and nitric oxide
	
  

(NO), among others

19-24

3
. The diversity of apoptotic insults resulting in E1A-induced

sensitivity raised questions about the potential mechanism(s) by which E1A might be
promoting apoptosis in transformed cells.

No tumors

Immune competent

a)

rodent models

Adenovirus

Immunocompromised

Tumor development

newborn rodents or
athymic (nude) rodents

b)

E1A+ cells

Death

E1A– cells

Survival

Innate killer cells

Figure 1. Adenoviral effects on tumor development and apoptosis. a) Adenovirus
infection or transfection with Adenovirus-transformed cells induce tumor formation in
immunocompromised rodents, but not in immune competent models. b) Innate killer
cells promote death in E1A-expressing cell lines, but not in E1A-negative cells.

Adenovirus E1A
Adenoviruses typically infect terminally differentiated cells and E1A is the first gene to
be transcribed within the nucleus. The E1A genomic unit codes for two alternative E1A
mRNAs, a 12S and a 13S form that have experimentally identical functionality and differ
in that the 13S form encodes an additional region of 46 amino acids 25,26. E1A proteins
across different adenoviral serotypes contain a series of conserved regions: CR1, CR2,
CR3 (specific to the 13S form), a PXDLS motif, and a conserved arginine at aa position
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2. All of the confirmed activities of these conserved motifs involve protein-protein
interactions, with no specific DNA-binding activity. Each of the conserved regions
interacts with different important cellular factors involved in cell cycle and
transcriptional control, and while the CR3 region of the 13S form has unique protein
interactions within the cell, 12S and 13S are able to carry out equivalent functions to
influence cell cycle control25.
The most extensively studied function of E1A is the deregulation of the cell cycle
G1/S transition by binding and disrupting the activity of several cell cycle regulators,
including key tumor suppressors such as Retinoblastoma protein (pRb). pRb and related
proteins interact with and inhibit the E2F family of transcription factors that promote
expression of genes required for transition to S phase 27. E1A binds pRB and precludes
binding and inhibition of E2F, which is then free to influence transcription and cell cycle
progression28 (Figure 2). This inhibition of key cell cycle regulators is the reason that
E1A is historically labeled an oncoprotein, even though it has been shown to sensitize
cells to a variety of immune apoptotic factors.

E1A
pRB

S phase

E2F

Figure 2. E1A promotion of cell cycle progression by inhibition of pRB. E1A
promotes cell cycle progression by binding and inhibiting pRB, an inhibitor of E2F
transcription factor. E2F is then free to induce expression of genes required for DNA
synthesis.
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E1A-induced sensitivity to apoptotic stress by inhibition of NF-κB defenses
Several mechanisms have been proposed for E1A-induced apoptotic sensitivity. For
example, it has been established that E1A promotes the accumulation of the anti-tumor
factor p53, a stimulator of apoptosis, suggesting p53 as a potential mediator of E1Ainduced sensitivity 29,30. However, there has been no supporting evidence to indicate that
p53 leads to E1A-induced sensitization to apoptosis 18.
It has been confirmed that the sensitivity to several classes of apoptotic stimuli is
due, at least in part, to the influence of E1A on NF-κB defenses against apoptosis. NFκB defenses have been studied extensively in the context of apoptosis induced by the
Tumor Necrosis Factor (TNF) family of cytokines 31,32. NF-κB is a transcriptional
regulator that leads to the expression of several anti-apoptotic proteins, and has been
proven to be the primary mode of defense against TNF. Interestingly, E1A sensitizes
certain types of cells to apoptosis under stress by TNF 20-22,33, suggesting a disruption of
the NF-κB defenses (Figure 3). It was also demonstrated that E1A is able to inhibit NFκB-dependent activity in the repression of HIV promoters 34-36. Several mechanisms of
E1A inhibition of NF-κB defenses have been proposed and have been supported by
experimental evidence. For example, E1A has been shown to inhibit IκB-kinase (IKK)
activity required for the activation of NF-κB 33,37, and also to inhibit the binding of NFκB subunits to their target promoters 38. In 2002, Cook et al. presented evidence that the
inhibition of NF-κB was related to E1A’s function in repression of Rb proteins 39. While
several potential mechanisms have been implicated, the full spectrum of E1A effects on
NF-κB activation has not been resolved.
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E1A
NF-κB
anti-apoptotic defenses

apoptosis

TNF

Figure 3. E1A inhibition of NF-κB anti-apoptotic defenses. E1A promotes apoptosis
in response to TNF by inhibiting NF-κB anti-apoptotic defenses.

E1A-induced sensitization to cytotoxic stress by regulation of caspase-2 activation
Due to the extensive evidence supporting E1A repression of NF-κB, a hypothesis
developed that this was the central mechanism in all modes of E1A-induced sensitivity.
In 2008, Radke et al. conducted a study to determine whether E1A repression of NF-κB
defenses could be implicated in E1A-induced sensitivity to several classes of apoptotic
injuries 40 . Macrophages are important innate immune cells involved in anti-tumor
activities and produce nitric oxide (NO), which efficiently kills E1A-expressing cells 23.
NO is able to activate NF-κB defenses 41-43, inspiring the hypothesis that the observed
sensitivity in response to E1A could be due to interruption of NF-κB by the viral
oncoprotein as previously described. Unexpectedly, the investigators found that E1Ainduced sensitivity to macrophage- and chemically-produced NO was not dependent on
the inhibition of NF-κB pathways. As NO injures mitochondria and causes a loss of
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mitochondrial membrane potential, leading to cell death, the group investigated whether
the pathway leading to mitochondrial injury was required for the observed sensitivity 44,45.
Caspase-2 directly injures the mitochondrial membrane, and NO had previously been
confirmed to activate caspase-2 46,47. The investigators found that inhibition of caspase-2
reduced sensitivity in E1A-expressing cells, and that activation of caspase-2 was critical
to the increased sensitivity of these cells 40. Thus, the study indicated that E1Adependent sensitization in response to NO injury is dependent on caspase-2 activation
(Figure 4). This suggests a qualitatively different mechanism by which E1A induces
sensitivity in cells: in addition to inhibiting anti-apoptotic defenses, E1A may be
positively influencing a pro-apoptotic cascade. Further research has focused on
determining the mechanism by which E1A might influence caspase-2 activation.

E1A
?
NO

Caspase-2

mitochondrial injury

apoptosis
Figure 4. E1A promotion of the Caspase-2 pro-apoptotic pathway. E1A promotes
apoptosis after NO cytotoxic stress by enhancing a pro-apoptotic cascade via an unknown
mechanism. Activation of caspase-2 is required for E1A-induced apoptosis 40.
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In 2002, Lassus et al. determined that activation of Caspase-2 in response to
cytotoxic stress such as mitochondrial NO is required for the permeabilization of the
mitochondrial membrane 48. When mitochondrial membrane integrity is compromised,
cytochrome-C and other mitochondrial factors are released, activating further caspases or
amplifying the caspase cascade 49. In unpublished data leading up to this study, our group
found that Caspase-2 activation is required for loss of mitochondrial membrane potential
in response to NO and genotoxic stress in E1A-positive cells.
Caspase-2 can be activated by a high molecular weight structure called the
PIDDosome, or by active caspase-3 50,51. The unpublished experiments referenced above
also addressed the mode of caspase-2 activation in E1A-expressing cells in response to
cytotoxic stress. Activation of Caspase-3 was not required to observe the caspase-2dependent sensitization of E1A-expressing cells in response to NO or the
chemotherapeutic drug etoposide, an agent that causes DNA damage. In sum, the Cook
group has determined that Caspase-2 is the apical mitochondria-injuring caspase in
response to NO in E1A-expressing cells. The observed effect of E1A-induced apoptotic
sensitization via the mitochondria must necessarily involve Caspase-2 activation
upstream of mitochondrial injury under conditions of NO stress. Furthermore, the mode
of Caspase-2 activation does not involve Caspase-3 upstream of Caspase-2 activation;
instead, caspase-2 activation in response to cytotoxic stress must proceed through the
PIDDosome.
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PIDD and the PIDDosome
Efficient activation of caspase-2 is accomplished on the PIDDosome, composed of P53induced protein with a Death Domain (PIDD), an adaptor protein (RIP)-Associated ICHICED-3 homologous protein with a Death Domain (RAIDD), and procaspase-2 50,52
(Figure 5). Accumulation of procaspase-2 in the PIDDosome allows for efficient
cleavage and activation of caspase-2.

PIDD DD
DD RAIDD CARD
CARD pro-caspase-2
Figure 5. Interactions of proteins in the PIDDosome. Schematic demonstrating the
interactions of PIDD, RAIDD, and pro-caspase-2 in the PIDDosome. PIDD and RAIDD
interact via Death Domains (DD), while RAIDD and pro-caspase-2 interact via CAspase
Recruitment Domains (CARD).

PIDD is a dynamic protein, able to promote opposing pathways depending on its
level of post-translational processing and subsequent protein associations. The prominent
PIDD isoform in humans (isoform 1) is expressed as a 910 aa protein with seven Leucine
Rich Repeats (LRRs) near the N terminus, two ZU-5 domains, and a C-terminal Death
Domain 53,54. At least two other PIDD isoforms are expressed in different classes of cells
and may have different effects on cell survival 55. Isoform 1 has been the subject of most
studies involving PIDD. The 100 kDA full-length protein is able to autoproteolyze to 48
kDa PIDD-N and 51 kDa PIDD-C fragments at position S446. The PIDD-C fragment
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further cleaves at S588 to produce a 37 kDa PIDD-CC fragment (Figure 6). The PIDDCC fragment is the functional component of the PIDDosome; within the PIDDosome, the
PIDD-CC death domain interacts with the death domain of RAIDD, and RAIDD’s
CAspase Recruitment Domain (CARD) interacts with the CARD of procaspase-2 53
(Figure 5).
While the PIDDosome provides a platform for cleavage of caspase-2, an
alternative complex formed by PIDD involves Receptor Interacting Protein 1 (RIP-1) and
the NF-κB complex factor NEMO 56. NEMO on this complex is subjected to
sumoylation, an essential step in the activation of NF-κB anti-apoptotic defenses. In
order to interact with RIP-1, PIDD must be processed to the PIDD-C form, as opposed to
PIDD-CC (Figure 6).
Thus, PIDD seems to have a dual role in cell survival and apoptotic pathways
depending on the degree of processing: PIDD-C promotes NF-κB defenses, while PIDDCC as part of the PIDDosome promotes caspase-dependent apoptotic pathways (Figure
6).
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100 kD

51 kD

37 kD

Figure 6. Schematic of PIDD auto-proteolysis to PIDD-C and PIDD-CC fragments.
Cleavage at S446 results in a PIDD-C fragment that promotes NF-κB anti-apoptotic
defenses. Further cleavage at S588 results in a PIDD-CC fragment, which facilitates proapoptotic caspase-2 activity.

Hypothesis and Experimental Approach
It is due to this dual role that we seek to understand the contribution of PIDD to E1Ainduced sensitivity in response to cytotoxic stress. PIDD seems to be a switch between
pro- and anti-apoptotic pathways, so it is tempting to consider how E1A might
influencing PIDD processing to turn the switch towards apoptotic sensitivity, while
simultaneously inhibiting anti-apoptotic defenses. In this study, we hypothesized that
E1A-induced sensitivity to cytotoxic stress is dependent on PIDD expression. We also
propose that E1A-induced sensitivity depends on PIDD processing to the terminal PIDDCC fragment.
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To determine the contribution of PIDD expression to E1A-induced sensitivity, we
generated knockdowns of PIDD in E1A-expressing NIH-3T3 cells and assayed
sensitivity to chemically-induced NO and the drug Etoposide, a chemotherapeutic agent
that leads to DNA damage and subsequent apoptosis. To understand the role of PIDDprocessing to the terminal -CC fragment in E1A-induced sensitivity, a PIDD-S588A
mutant that is incapable of cleaving to PIDD-CC was generated and also assayed for
sensitivity to NO and etoposide. Sensitivity assays included MTS metabolic activity
assay, which gave a measure of cell survival after treatment with the cytotoxic stressors.
We also measured the change in mitochondrial membrane potential (MMP) of treated and
untreated cells by DilC1(5) staining and global apoptotic character by Annexin V
staining. If PIDD expression and PIDD processing is required for E1A-induced
sensitivity to cytotoxic stress, PIDD knockdowns and PIDD-processing mutants should
demonstrate reduced sensitivity by these various assays.

	
  

CHAPTER II
MATERIALS AND METHODS
Generation of PIDD-knockdowns and PIDD-S588A mutants
NIH-3T3 mouse fibroblasts and all derivatives expressing Ad5 12S E1A were grown in
DMEM with 5% bovine calf serum 20,40. PIDD-knockdown E1A+ cells were generated
from 12S E1A+ cells by infection with lentiviral particles targeting mouse PIDD (siRNA
target sequence AGCTTTAAACTTGACTCGA) or a standard non-targeting control
(Dharmacon). The lentiviral constructs also contained a puromycin resistance marker
and encoded for GFP. Single colonies were selected from 7.5 µg/ml puromycin media
and screened for GFP expression by flow cytometry, expression of E1A by western blot
using M73 monoclonal antibody (Santa Cruz Biotechnology), and suppressed expression
of PIDD (Figure 8).
Human fibrosarcoma HT1080 cells (H4) and E1A-expressing derivatives (P2)
were maintained in 10% Fetal Bovine Serum in RPMI. E1A+ cells were transfected with
one of five pLKO.1 vectors encoding shRNA sequences targeting human PIDD
(CTTTGTCTTCTACTCGCACCT; GACTGTTCCTGACCTCAGATT;
GACCTCAGATTTGGACAGCTT; CTGCTTTGTCTTCTACTCGCA;
CCTCGATCTCTCTCAGAATCT; Thermo Scientific). Single colonies were selected in
2.5 µg/ml puromycin and screened for suppressed expression of PIDD by western blot
using anti-PIDD monoclonal antibody (AL233, Alexis; Figure 10).
13	
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PIDD S588A mutants were generated in 12SA E1A-expressing cells using a
plasmid encoding PIDD-S588A flag-tagged at the C-terminal end, which had been
obtained from Jurg Tschopp 53. The PIDD gene was cloned into vector pcDNA3.1 (+)
Hygromycin (Invitrogen) by HindIII/NotI digestion and ligation, and the resulting
construct was electroporated into the E1A+ line. S588A mutant cells were selected in
media containing 200 µg/ml hygromycin, then screened for expression of E1A and Flagtagged PIDD-S588A by western blot (Sigma anti-Flag M2 antibody; Figure 11).
Cell death assays
Cell lines were treated with increasing doses of DETA-NONOate (Cayman Chemical) or
etoposide (Sigma) overnight (18 hours) in 96 well plates and subjected to a colorimetric
cell viability assay (CellTiter 96 Non-Radioactive Cell Proliferation assay from
Promega). Absorbance values were read on a plate reader at 570 nm as per instructions
and cell death was expressed as a ratio of treated/untreated absorbance values for each
cell line.
Flow cytometry
To assess mitochondrial membrane potential, cells were treated with DETA-NONOate or
etoposide as described, then stained with 25 nM MitoProbe Dil1C(5) as per kit
instructions (Life Technologies). To observe global apoptotic phenotype, cells were
treated with DETA-NONOate or etoposide and stained with both Dil1C(5) and PEAnnexin V (Life Technologies) as per instructions. Data were acquired on a BD Accuri
C6 Flow Cytometer and processed and analyzed using FlowJo X 10.0.7r2 (Tree Star
Inc.). Forward scatter versus side scatter plots were used to gate around non-debris
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values and the same gate was applied to all corresponding data to generate histograms of
DilC1(5) staining. All assigned quadrants in the DilC1(5)/Annexin V multiplex
experiments remained consistent, permitting a comparison of cell populations across cell
lines.
Statistical Analysis
Student’s t-test was used for statistical analysis, using Systat SigmaPlot 12.3 software. n
≥ 3 for all statistically analyzed data, and data are expressed as mean ± SEM.

	
  

	
  

CHAPTER III
RESULTS
Generation and selection of PIDD-knockdown and PIDD-mutant E1A-positive cells
PIDD knockdown cell lines
To determine whether PIDD is required for E1A-induced sensitization to
apoptosis, I generated PIDD knockdowns of mouse fibroblast NIH-3T3 E1A-expressing
mutants. The E1A positive parent line had been used previously by the Cook lab for
studies investigating the effect of E1A on NF-κB and apoptotic pathways 40; therefore, I
generated the knockdowns in this background. I introduced into the E1A positive cell
line lentiviral vectors that encoded shRNAs specific for PIDD as well as puromycin
resistance and GFP, such that expression of the shRNAs correlated with GFP expression
in the transduced lines. Cell lines resistant to puromycin were initially screened for GFP
expression by flow cytometry. Two separate PIDD knockdown lines (iPIDD-1 and
iPIDD-2) displayed GFP expression over the 3T3/E1A-negative and E1A-positive parent
lines (Figure 7). In parallel, I introduced a lentiviral vector that encoded a control
scrambled shRNA sequence; this transduced E1A+ line also expressed GFP, indicating
successful expression of the construct and shRNA (Figure 7).

16	
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3T3
E1A+
iPIDD-1
iPIDD-2
scRNA

Figure 7. GFP expression in PIDD knockdown lines. Cell lines were screened for
GFP expression by flow cytometry to indicate successful expression of PIDD shRNAs.

To verify that levels of PIDD protein were reduced in the knockdown cell lines, I
evaluated PIDD protein levels by western blot (Figure 8). The parental E1A-negative
3T3 cell line and the E1A-positive cell line (lanes 1 and 2, respectively) exhibited
equivalent expression of full-length and PIDD-C processed fragments. The E1A-positive,
PIDD-knockdown cell lines (iPIDD-1 and iPIDD-2) showed reduced PIDD expression
for each fragment (lanes 3 and 4). The E1A-positive line expressing the scrambled
shRNA had no alteration of PIDD levels (lane 5). iPIDD-1 exhibited a more extensive
knockdown of PIDD than did iPIDD-2. Despite several repeated attempts to create
knockdowns by infection with the lentiviral constructs, we could not produce or confirm
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a complete PIDD knockdown in either of these lines, and performed further experiments
on these partial knockdowns.

(100kD)

(50kD)

Figure 8. Immunoblot of mouse PIDD-knockdown cell lines. Anti-PIDD
immunoblots of PIDD-knockdowns (iPIDD-1 and iPIDD-2) were compared to 3T3 E1Anegative and E1A-positive parent lines, as well as an E1A+ line transfected with a
construct expressing a scrambled shNA. Whole cell lysates were run on SDS-PAGE gels
and blotted with mouse anti-PIDD antibody to determine positions of PIDD protein.
Anti-actin blotting confirmed equal applications of lysates, and anti-E1A confirmed
expression of E1A across the E1A+, PIDD knockdown, and scrambled shNA lines.

In order to correlate apoptotic sensitivity to PIDD expression, transduced cell
lines that were resistant to puromycin and expressed GFP were screened for reduced
sensitivity to NO over several concentrations of the NO generator DETA-NONOate.
Figure 9 represents a selection of cell lines that were tested for sensitivity to NO by MTS
metabolic assay. Cell lines 2D and 2E consistently showed lower cell death than the
E1A+/PIDD-competent parent line (red line labeled 12SA), and comparable cell death as
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the 3T3 E1A-negative line (blue line labeled 3T3). Cell lines 2D and 2E were labeled
iPIDD-1 and iPIDD-2 respectively, and chosen for further analysis to determine if the
decreased sensitivity to NO is related to PIDD function. Cell lines 1E and 2B had
comparable NO cell death to the E1A+ parent line and were not chosen for further
analysis.

Figure 9. Selection of PIDD knockdown lines with reduced sensitivity to NO
treatment. Puromycin-resistant and GFP-positive lines were treated with several
concentrations of DETA-NONOate for 18 hours overnight. Cell death was assessed by
MTS assay and expressed as a percent of cell death of untreated cells.
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We also attempted to generate PIDD knockdowns of an E1A+ derivative of the
H4 human fibroblast cell line. I transfected E1A+ cells with one of several vectors
designed to target several distinct regions of transcript for the human PIDD protein, then
assessed the presence of PIDD by immunoblot with anti-PIDD antibody. Unfortunately,
I did not observe a knockdown effect on any protein bands predicted to be the various
fragments of PIDD (Figure 10, lanes 1-7). Additionally, the exact identity of the PIDD
fragments was unclear, with several bands approaching but not exactly matching the
predicted sizes. Full-length PIDD is 100 kD; we observed two bands between 100 and
150 kD (position A on Figure 10). PIDD-C is 51 kD, however the immunoblot shows a
strong band at around 60 kD and several lighter bands between 50 and 60 kD (position
B). Finally, the PIDD-CC fragment should be 37 kD, but the blot showed no band at this
position. Rather, the lowest band at position C was positioned well above 37 kD and is
our best approximation of PIDD-CC. The complicated banding profiles of PIDD in this
blot (and others) may represent at least three isoforms that are known to be expressed in
human cell lines 55. Regardless, we were unsuccessful in knocking down any of the
predicted PIDD fragments in the transfected lines: the banding patterns clearly matched
those of the H4 and E1A+ parent lines, indicating that all PIDD fragments were equally
expressed and processed in all transfected lines.
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PIDD knockdowns
kD
150

H4

E1A

1
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6
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α-PIDD

*
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37

Figure 10. Immunoblot of human PIDD-knockdown lines. Whole cell lysates were
run on SDS-PAGE gels and blotted with human anti-PIDD antibody to determine
positions of PIDD protein. A represents potential full-length PIDD fragments. B
represents potential PIDD-C fragments. C represents a potential PIDD-CC fragment.

PIDD mutant cell lines
We hypothesized that PIDD processing to the PIDD-CC fragment is required for
E1A-induced sensitivity to cytotoxic stress. To test this hypothesis and determine the
effect of PIDD processing on E1A-induced sensitivity, a C-terminal flag-tagged PIDD
processing-mutant (S588A) was expressed in the E1A-positive mouse fibroblast cell line.
This mutant construct has been described and used in several studies, and is unable to
auto-cleave to the PIDD-CC fragment required for PIDDosome activation of Caspase-253.
The overexpressed mutant PIDD only cleaves to PIDD-C and results in a dominantnegative mutation, accumulating to prevent the formation of the PIDDosome with the
necessary endogenous PIDD-CC fragments. On western blots, we observed the flagtagged full length and PIDD-C proteins (Figure 11); we did not observe the PIDD-CC
band (data not shown). These data confirm that the cell line successfully overexpressed
the flag-tagged PIDD processing mutant.
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(100kD)
(50kD)

Figure 11. Immunoblot of mouse PIDD-S588A mutant cell lines. Whole cell lysates
were run on SDS-PAGE gels and blotted with anti-flag to determine positions of flagtagged PIDD. Anti-actin blotting confirmed equal applications of lysates, and anti-E1A
confirmed expression of E1A in E1A+ parent line and the S588A mutant. * = nonspecific antibody interactions.

Cytotoxic sensitivity of PIDD-knockdown and PIDD-processing mutant lines
To determine whether PIDD was required for the sensitization of E1A-expressing cells,
we compared cell death resulting from NO- and Etoposide-mediated cytotoxic stress of
E1A-positive/PIDD-knockdown cells and their PIDD-competent parent lines. Cell death
was determined by MTS metabolic assay and represented a measure of sensitivity to the
chemical or drug treatment. After treatment with NO, cell death of the knockdown lines
was about half of that observed for the E1A+/PIDD+ parent line (Figure 12). The non	
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targeting shRNA expression line (labeled scRNA) did not have any unintended effects on
cell sensitivity. These results indicate that PIDD expression is required for E1A-induced
sensitivity to NO injury.

NS
p<0.003
p=0.0248
p<0.003

Figure 12. Cell death in PIDD-knockdowns and E1A+ cells after NO treatment.
Cells were exposed to 250 µM NO generator DETA-NONOate for 18 hours overnight.
Cell death was assessed by MTS assay and expressed as a percent of cell death of
untreated cells. n=3, mean±SEM.

The PIDD knockdown lines also had lower cell death when compared to the
PIDD-competent line as a result of etoposide treatment (Figure 13). However, cell death
was significantly higher for both knockdown lines when compared to the 3T3 parent line.
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It is possible that the partial knockdown of PIDD accounts for the intermediate phenotype
between the E1A+ and E1A-negative parent lines in response to etoposide. Alternatively,
the intermediate phenotype may be due to the fact that etoposide has a distinct DNAdamaging mechanism compared to NO. Regardless, we can conclude that PIDD
expression is required for the complete sensitization effect of E1A for both NO and
etoposide treatment.

p<0.001
p=0.003
p<0.001
p=0.003

Figure 13. Cell death in PIDD-knockdowns and E1A+ cells after etoposide
treatment. Cells were exposed to 10 µM Etoposide for 18 hours overnight. Cell death
was assessed by MTS assay and expressed as a percent of cell death of untreated cells.
n=3, mean±SEM.
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To determine whether E1A-induced sensitivity is due to PIDD processing to the
PIDD-CC fragment, we also compared the cell death sensitivity of the PIDD S588A
mutant to the parent lines. We found that the E1A+/PIDD-S588A mutant exhibits
significantly less cell death than the E1A+/PIDD-competent line (Figure 14), indicating
that the inability to process to the PIDD-CC form makes the mutant cell line less
sensitive to NO challenge than the E1A line with endogenous PIDD. Thus, PIDD
processing to the –CC fragment is also required for E1A-induced sensitivity to NO.
The PIDD-processing mutant was also significantly less sensitive to the effects of
etoposide poisoning (Figure 15). The mutant exhibited an intermediate phenotype
between the 3T3 and E1A+ cell lines in response to etoposide. As with the PIDD
knockdowns, this could be due to the difference in cytotoxic damage caused by NO and
etoposide. Regardless, the data indicate that PIDD processing to the –CC fragment is
required for the full sensitization effect of E1A due to cytotoxic stress.
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NS
p=0.003

Figure 14. Cell death in PIDD-S588A mutant and E1A+ cells after NO treatment.
Cells were treated with 250 µM NO generator DETA-NONOate for 18 hours overnight.
Cell death was assessed by MTS assay and expressed as a percent of cell death of
untreated cells. n=3, mean±SEM.

p<0.001
p<0.001

Figure 15. Cell death in PIDD-S588A mutant and E1A+ cells after etoposide
treatment. Cells were exposed to 10 µM Etoposide for 18 hours overnight. Cell death
was assessed by MTS assay and expressed as a percent of cell death of untreated cells.
n=3, mean±SEM.
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Mitochondrial Membrane Potential of PIDD knockdown and mutant lines
In unpublished data, our group has confirmed that E1A influence on caspase-2 activation
in response to cytotoxic injury is upstream of mitochondrial injury and loss of membrane
potential. To determine if this effect on MMP is dependent on PIDD, these new cell lines
were assessed for loss of MMP in response to cytotoxic stress by staining with DilC1(5),
a dye that accumulates within healthy mitochondria and is lost as the mitochondrial
membrane is injured.
In response to NO treatment, E1A-positive cells lose more MMP than their E1Anegative parent line (Figure 16; gray histograms represent untreated cells, empty
histograms indicate NO-treated cells). The 3T3 parent line even seems to increase in
MMP, possibly as a result of cell survival mechanisms intended to save the cell.
Markedly different from the response of the E1A+ line is the E1A+/PIDD-knockdown
response, which does not show a change of MMP in response to NO. Thus, the decrease
in PIDD expression in these cells seems to decrease E1A-induced mitochondrial injury.
The E1A+/PIDD-processing mutant loses MMP in response to treatment, but to a lesser
extent than can be observed for the E1A+ cells. The inability to process to the PIDD-CC
fragment seems to decrease the effect of E1A on cell mitochondrial sensitivity. Figure
17 represents three repeated experiments and shows the average MMP of NO-treated
cells as a percentage of untreated cells. The E1A+ cell line has significantly lower MMP
after treatment than either the E1A+/PIDD-kd line or the E1A+/PIDD-mutant line. Thus,
PIDD expression and processing are necessary for E1A-induced loss of MMP as a result
of NO cytotoxicity.
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Figure 16. Loss of MMP in PIDD-knockdown and PIDD-mutant lines after NO
treatment. Cell lines were treated with 250 µM of DETA-NONOate for 18 hours and
stained with DilC1(5), then analyzed by flow cytometry to determine the degree of
mitochondrial injury as a result of cytotoxicity. Filled histograms represent untreated
cells and empty histograms are the NO-treated cells.
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p=0.0475
p=0.001

Figure 17. Quantification of MMP loss for PIDD-knockdown and PIDD-mutant
lines. Three DilC1(5) staining experiments from figure 7 were averaged for each cell
line. Loss of MMP of treated cells was expressed as a percent of MMP of untreated cells.
n=3, mean±SEM.

Figure 18 shows histograms for MMP for etoposide-treated cells, which resemble
the results of NO-treated cells. E1A+ cells show reduced MMP as a response to
etoposide, compared to the E1A-negative parent lines. Both the E1A+/PIDD-kd and
E1A+/PIDD-mutant lines exhibit either no loss or reduced loss of MMP compared to the
E1A+ line after etoposide treatment. Thus, the E1A-induced mitochondrial sensitivity
after either NO or etoposide cytotoxic stress seems to be due to PIDD expression. It is
not clear from these data that PIDD processing is required for E1A-induced sensitivity to
cytotoxic stress.
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Figure 18. Loss of MMP in PIDD-knockdown and PIDD-mutant lines after
etoposide treatment. Cell lines were treated with 10 µM of etoposide for 18 hours and
stained with DilC1(5), then analyzed by flow cytometry to determine the degree of
mitochondrial injury as a result of cytotoxicity. Filled histograms represent untreated
cells and empty histograms are the etoposide-treated cells.

To further characterize the sensitivity of cell lines to cytotoxic stress, cells were
double stained with DilC1(5) and Annexin-V, an indicator of global cell death. Multiplex
staining in two repetitions of this experiment clearly showed the progression of the cells
towards a lower MMP in combination with a reduction in global cell injury. In figures
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19a and 19b, cells in Quadrant 1 (Q1) have low Annexin-V and high DilC1(5) counts,
indicating healthy cells with high MMP. Those cells in Q3 have lost mitochondrial
staining and gained Annexin-V staining, indicating apoptosis.
In Figure 19a, each of the cell lines has roughly equivalent values across all four
quadrants in the untreated graphs, with very few cells indicating apoptosis in Q3. Upon
the addition of NO, the 3T3 parent line does not transition towards an apoptotic
phenotype, while roughly 40% of the E1A+ cells become apoptotic. The E1A+/PIDDknockdown line (E1A-iPIDD) also transitions to apoptosis at about 17%, but clearly less
than the E1A+ cells, indicating less apoptotic sensitivity to cytotoxic stress as a result of
a lack of PIDD. We may have observed even starker differences between the PIDD-kd
and E1A+ lines if the knockdown effect had been more complete.
The plot for the E1A+/PIDD-processing mutant (E1A-mtPIDD) in figure 19a
shows less of a transition to apoptosis after NO treatment than that of the E1A+ line,
however the proportions are very close (30% versus 39% apoptotic cells). Thus, the
mutant-processing PIDD does not seem to prevent the cells from experiencing some
transition to apoptosis as obviously as can be observed by the PIDD knockdown.
The difficulty with this multiplex staining assay is demonstrated in figure 19b, in
which the protocol remained the same but the results showed increased progression to the
apoptotic quadrant for the E1A+, iPIDD, and mtPIDD lines after NO treatment. For
example, the Q3 population of the iPIDD line is only 17% in figure 19a, but 27% in 19b.
The stability of the cells may be affected by the successive staining with DilC1(5)
followed by Annexin V, which call for different buffer solutions and extended staining
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periods; thus, the assay is fastidious and inconsistent. However, while the lines were less
stable in 19b than in 19a, both experiments indicate that the iPIDD line is less sensitive to
NO treatment compared to the E1A+ line, suggesting that PIDD expression is necessary
for E1A-induced sensitivity to apoptosis in response to NO treatment. The results for the
mutant line in these experiments do not clearly indicate that PIDD processing is required
for E1A-induced sensitivity to apoptosis.
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Figure 19a. Multiplex MMP and apoptosis staining of PIDD-knockdown and PIDDmutant cell lines. Cells were treated with DETA-NONOate at 250 µM for 18 hours,
then stained with DilC1(5) and PE-Annexin V. Cells were analyzed by flow cytometry to
visualize relative MMP and global cell apoptotic character. Quadrant 1 (Q1) represents
high MMP and low phosphatidylserine staining of healthy cells, while Quadrant 3 (Q3)
represents low MMP and high PS staining of cells undergoing apoptosis. Figures 19a
and 19b (below) represent two repetitions of this experiment.
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Figure 19b. Repeat of multiplex staining of knockdown and mutant lines. Methods
for this experiment were identical as described for figure 19a.
	
  

	
  

CHAPTER IV
DISCUSSION
The experiments presented in this thesis have attempted to determine if there is a
requirement for PIDD protein and terminal PIDD processing in E1A-induced sensitivity
to certain cytotoxic stressors. Previous research indicated that E1A-induced sensitivity to
NO was caspase-2 dependent, and unpublished data out of the Cook lab indicate that the
caspase-2 activation is upstream of mitochondrial injury and likely proceeds via the
PIDDosome. Using two E1A+ cell lines with a partial knockdown of PIDD protein, I
determined that PIDD deficiency had verifiable effects on the sensitivity of E1Aexpressing cells. PIDD-knockdown cells exhibited less cell death in response to
cytotoxic stressors than E1A+/PIDD+ cells, as measured by a metabolic activity assay
(Figures 12 and 13). PIDD-KD cells also lost less mitochondrial membrane potential,
and exhibited less of a global apoptotic phenotype as a result of NO and etoposide
treatment (Figures 16-19). Thus, PIDD expression is required for E1A-induced
sensitivity to cytotoxic stresses. Unfortunately, I was only able to create partial
knockdowns of PIDD protein in these lines, which limits the conclusions that can be
drawn from these studies in regards to the exclusive requirement of PIDD in E1Ainduced apoptotic sensitivity; that is, I cannot rule out that other PIDD-independent
mechanisms may be involved in producing the complete sensitization effect.
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PIDD-knockdown lines were consistently less sensitive than the E1A+/PIDD+
lines; however, in some cases, the knockdowns did not display as much resistance to
cytotoxic stressors as the E1A-negative parent line 3T3: both knockdowns were
significantly more sensitive to Etoposide than the 3T3 line (Figure 13), and iPIDD-2 was
also more sensitive to NO than the 3T3 line (Figure 12). There are several possibilities
for why our knockdowns do not completely eliminate the E1A-induced sensitivity in
response to cytotoxic stresses: 1) The incomplete knockdown of PIDD in our lines
means that some of the protein is able to promote caspase-2 activation and subsequent
apoptosis. 2) As mentioned above, it is possible that E1A regulates some alternative
pathway that leads to caspase-2 activation and subsequent mitochondrial injury. 3) The
intermediate sensitivity of the knockdown lines compared to the E1A+ and E1A– lines is
obvious when etoposide is the stressor. As etoposide and NO have different mechanisms
of DNA damage, E1A may not be working through PIDD activity and caspase-2
activation to induce sensitivity in response to etoposide; another mechanism may be
involved instead. Beyond these possibilities, these experiments confirm that the presence
of PIDD protein is required for the complete sensitization that cells experience by E1A
expression. It seems important to repeat these experiments with complete PIDD
knockdowns or in a cell line with deleted PIDD gene, to determine whether sensitivity
can be reduced to levels approximating the E1A-negative parent lines.
We also examined whether a dependence on PIDD expression meant that the
mechanism for E1A-induced sensitivity required PIDD-processing to the terminal PIDDCC fragment and, thus, activation of the PIDDosome towards caspase-2 activation. The
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E1A+/PIDD-S588A processing mutants were less sensitive to cytotoxic stress than the
E1A+/PIDD+ cell line. Cell death as measured by metabolic activity was significantly
reduced in the PIDD-S588A line as compared to the E1A+ line for both NO and
etoposide treatment, although it was also significantly greater than the E1A-negative 3T3
parent line in the case of etoposide (Figures 14 and 15). Quantification of MMP loss in
response to NO indicated that the mutant did have significantly more retention of MMP
in response to NO treatment (Figure 17). That the PIDD processing mutant had
intermediate phenotype between the E1A+ and E1A-negative lines could point to at least
two different possibilities: 1) PIDD is acting independently of PIDD processing and the
PIDDosome to activate caspase-2 or induce mitochondrial injury via the NF-κB pathway,
or 2) that the level of exogenous expression of the PIDD S588A mutant is not enough to
overcome the effect of endogenous wild-type PIDD and PIDD-CC in formation of
functional PIDDosomes. Further studies may be performed with either stronger PIDD
S588A mutant expression or by inhibiting the cleavage of endogenous PIDD to the
PIDD-CC form. Also, inhibition of PIDDosome formation with knockdowns or mutants
of the RAIDD adaptor protein could reveal the importance of the functional PIDDosome
on E1A-induced sensitivity.
For this study we also attempted to generate PIDD knockdowns of human
fibroblast cell lines: a HT1080 parent line (H4), and its derivative expressing E1A. Antihuman PIDD antibodies seem to have several non-specific interactions, making it
difficult to identify the full-length PIDD and processed forms. Alternatively, it is
possible that several isoforms of PIDD may be present in this fibroblast cell line, and that
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the interactions reflect the processing of diverse PIDD isoforms. Regardless, we could
not observe knockdowns of any band predicted to be the PIDD full-length or processed
fragments in western blots. Previous studies have confirmed the existence of at least 3
PIDD isoforms expressed differentially across many human cell lines 55 . As opposed to
our mouse cell lines––where there is not yet evidence for more than one PIDD isoform––
these human isoforms may function in opposing fashions and complicate the
interpretation of studies examining PIDD function. Studies attempting to determine the
effect of PIDD on E1A-induced sensitivity in humans may require consideration of the
activity of a whole suite of PIDD proteins, as opposed to a seemingly simpler
homologous system in mice. Such studies may involve the overexpression of individual
PIDD isoforms in E1A-expressing cells to determine their effect on E1A-induced
sensitivity.
Immediate experiments following this study should confirm and correlate the
processing of Caspase-2 in PIDD-knockdown or mutant cells to E1A-induced sensitivity.
Western blots of Caspase-2 processing could confirm activation of the caspase in PIDDknockdown cells in response to NO and etoposide-induced stress. Flow cytometry
experiments with staining for active caspase-2 in combination with indicators of MMP
will provide visual evidence of whether cells that lose MMP also exhibit caspase-2
activation, and whether that condition is dependent on PIDD expression or processing.
Further studies should attempt to elucidate potential mechanisms of E1A-induced
caspase-2 activation and cytotoxic sensitivity. We have provided evidence that PIDD
expression is required for E1A-induced sensitivity to cytotoxic stress: how might E1A be
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directly or indirectly influencing PIDD or the PIDDosome? One possibility is that E1A
drives efficient autoproteolysis of PIDD to the PIDD-CC form, leading to formation of
the PIDDosome and caspase-2 activation. It will be important to determine whether E1A
interacts with potential factors involved in PIDD processing. PIDD is auto-proteolyzed
to the PIDD-C and subsequently PIDD-CC form, but the process at either cleavage site
may be constitutively repressed by unknown factors. E1A may be interacting with and
inhibiting factors involved in repression of PIDD-CC cleavage, or indirectly driving
processes that inhibit such cleavage repressors. This may have a compound effect, as
efficient cleavage to the PIDD-CC site not only contributes to PIDDosome formation and
caspase-2 activation, but also depletes the pool of PIDD-C fragments required for NF-κB
activation, as described in the introduction. To understand the potential interactions and
pathways by which E1A is involved in PIDD processing, we will need to clarify the
endogenous mechanisms involved in regulation of PIDD.
Ultimately these studies will lead to greater understanding of the many
mechanisms utilized by the E1A adenoviral protein to sensitize cells to a variety of
apoptotic insults. Hopefully, this knowledge will contribute to improvement of the
arsenal of E1A-based cancer therapeutics by directing more targeted and efficient activity
of the viral protein on endogenous PIDD.
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